DE000BAY0017
© BusinessWire
23.11.2025
BAYN
LISTED
XETR
Bayer’s Asundexian Met Primary Efficacy and Safety Endpoints in Landmark Phase III OCEANIC-STROKE Study in Secondary Stroke Prevention
News Preview
Bayer today announced positive topline results from the global Phase III study OCEANIC-STROKE, with its investigational, once daily, oral FXIa inhibitor asundexian. The study met its primary efficacy and safety endpoints. Asundexian 50 mg once daily significantly reduced the risk of ischemic stroke compared to placebo, both in combination with ant...
Themefolio
Profiler
Peergroup
© EQS Newswire
23.11.2025
BAYN
LISTED
XETR
Asundexian von Bayer erreicht primäre Wirksamkeits- und Sicherheitsendpunkte in zulassungsrelevanter Phase-III-Studie OCEANIC-STROKE zur Sekundärprävention von Schlaganfällen
News Preview
Leverkusen / Berlin, 23. November 2025 – Bayer hat heute positive Topline-Ergebnisse aus der globalen Phase-III-Studie OCEANIC-STROKE mit dem Prüfpräparat Asundexian, einem einmal täglich oral verabreichten FXIa-Hemmer, bekannt gegeben. Die Studie erreichte ihre primären Wirksamkeits- und Sicherheitsendpunkte. Asundexian, 50 mg einmal täglich, redu......
Themefolio
Profiler
Peergroup
© BusinessWire
20.11.2025
BAYN
LISTED
XETR
U.S. FDA Approves HYRNUO® (sevabertinib) for Previously Treated Patients with HER2-Mutated Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
News Preview
Bayer announced today that the U.S. Food and Drug Administration (FDA) has approved HYRNUO® (sevabertinib), an oral, reversible, tyrosine kinase inhibitor (TKI), for the treatment of adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors have HER2 (ERBB2) tyrosine kinase domain (TKD) activat...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Leerverkaufsstatistiken, Hedge-Fund Aktivitäten und viele weitere nutzerwertige Informationen benutzerfreundlich aufbereitet
© BusinessWire
10.11.2025
BAYN
LISTED
XETR
Bayer Launches “Science Delivers” Campaign Celebrating the Transformative Power of Science
News Preview
Today, on World Science Day, Bayer is proud to launch its “Science Delivers” campaign, a nationwide initiative celebrating how science delivers answers, hope, and progress for all Americans—every day, in the moments that matter most.
From the medicine that keeps us healthy to the technology that connects and helps feed us, to the innovations tha...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© BusinessWire
06.11.2025
BAYN
LISTED
XETR
Dr. Judith Hartmann to Become New Chief Financial Officer of Bayer AG
News Preview
The Supervisory Board of Bayer AG has appointed Dr. Judith Hartmann to the company’s Board of Management, effective March 1, 2026. She will succeed Wolfgang Nickl as the company’s Chief Financial Officer (CFO) on June 1, 2026, following his planned retirement at the end of May 2026. Dr. Hartmann is currently an Operating Partner at Sandbrook Capit...
Themefolio
Profiler
Peergroup
© BusinessWire
06.11.2025
BAYN
LISTED
XETR
KERENDIA® (finerenone) Meets Primary Endpoint in Phase III Clinical Trial for Adults with Type 1 Diabetes and Chronic Kidney Disease
News Preview
Bayer today announced new Phase III investigational data from the pivotal FINE-ONE trial showing that KERENDIA® (finerenone) significantly reduced urine albumin-to-creatinine ratio (UACR) from baseline over six months by 25% compared to placebo in patients with type 1 diabetes (T1D) and chronic kidney disease (CKD) who were receiving standard of c...
Themefolio
Profiler
Peergroup
© BusinessWire
24.10.2025
BAYN
LISTED
XETR
Bayer’s Lynkuet® (elinzanetant), the First and Only Neurokinin 1 and Neurokinin 3 Receptor Antagonist, Receives FDA Approval for Moderate to Severe Hot Flashes Due to Menopause
News Preview
Bayer announced today the U.S. Food and Drug Administration (FDA) has approved Lynkuet® (elinzanetant) 60mg capsules, the first and only dual neurokinin (NK) targeted therapy,1 neurokinin 1 (NK1) and neurokinin 3 (NK3) receptor antagonist, for the treatment of moderate to severe hot flashes due to menopause.1 Inhibition of Substance P and Neurokin...
Themefolio
Profiler
Peergroup
© BusinessWire
21.10.2025
BAYN
LISTED
XETR
Late-breaking data from Phase III OCEANIC-STROKE study accepted for presentation at World Stroke Congress 2025
News Preview
Bayer will present methods and baseline characteristic data from the global Phase III OCEANIC-STROKE study with the investigational agent asundexian, in a late-breaking presentation at the upcoming 17th World Stroke Congress, being held in Barcelona, Spain from October 22 – 24.
Bayer presentations on OCEANIC-STROKE include:
Factor XIa (FXIa)...
Themefolio
Profiler
Peergroup
© BusinessWire
07.10.2025
BAYN
LISTED
XETR
Bayer Partners with Cornfed Farms to Create First ForwardFarm in Midwest
News Preview
Bayer is proud to announce that Cornfed Farms, a fourth-generation farm operated by the Mohr family, has been designated as the first Bayer ForwardFarm site in the Midwest and the only ForwardFarm in the United States. This recognition places Cornfed Farms as one of 16 farms around the globe, highlighted by Bayer as committed to advancing regenera...
Themefolio
Profiler
Peergroup
© BusinessWire
07.10.2025
BAYN
LISTED
XETR
One A Day® Unveils Bold New Brand Identity and Platform: “The ONE for you”
News Preview
One A Day®, the multivitamin and supplement brand by Bayer rooted in 80+ years of nutritional science, today announced a bold new brand identity and positioning designed to better connect with today’s consumers and their evolving health needs. The rebrand, rolling out nationwide this fall, introduces a refreshed visual identity, packaging, and pur...
Themefolio
Profiler
Peergroup
© BusinessWire
07.10.2025
BAYN
LISTED
XETR
BlueRock Therapeutics reports positive 36-month results from Phase I trial of bemdaneprocel for treating Parkinson’s disease
News Preview
Bayer AG and its wholly owned, independently operated subsidiary BlueRock Therapeutics LP, a clinical stage cell therapy company, today announced positive 36-month data from exPDite, a Phase I clinical trial of bemdaneprocel, an investigational cell therapy for the treatment of Parkinson's disease (PD). The data were presented on October 6th at th...
Themefolio
Profiler
Peergroup
© BusinessWire
29.09.2025
BAYN
LISTED
XETR
Bayer Selects Interpublic as Global Media, Production and Creative Agency Partner for Consumer Health Division
News Preview
The Consumer Health division of Bayer has selected Interpublic Group (NYSE: IPG) as the global agency partner for all creative, production and media, responsible for marketing activities for some of the most trusted and well-known brands in self-care.
The selection of an integrated agency across brands and regions represents a new era in how Bay...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© BusinessWire
25.09.2025
BAYN
LISTED
XETR
Bayer Canada Announces New Distribution Partnership for ADALAT® XL® (nifedipine extended-release tablets) 30 mg Tablets in Canada
News Preview
Bayer Canada is pleased to announce a new partnership with Mint Pharmaceuticals Inc. for the distribution of ADALAT® XL® 30 mg tablets1 in Canada. This strategic collaboration took effect on September 3, 2025.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250925537941/en/From Left to...
Themefolio
Profiler
Peergroup
© BusinessWire
25.09.2025
BAYN
LISTED
XETR
Bayer to Highlight New Data for KERENDIA® (finerenone) at Heart Failure Society of America (HFSA) Annual Scientific Meeting 2025
News Preview
Bayer announced today that data from across the KERENDIA® (finerenone) comprehensive clinical trial program will be presented at the Heart Failure Society of America (HFSA)’s Annual Scientific Meeting in Minneapolis, Minnesota, September 26-29, 2025.
In July 2025, the U.S. Food and Drug Administration (FDA) approved a new indication for KERENDIA...
Themefolio
Profiler
Peergroup
© BusinessWire
22.09.2025
BAYN
LISTED
XETR
Bayer First Company to Advance Cell Therapy as Well as Gene Therapy Against Parkinson’s Disease
News Preview
Bayer announced today progress for two potential therapies against Parkinson’s disease (PD). A first participant received randomized treatment in the pivotal Phase III clinical trial, exPDite-2, of bemdaneprocel, an investigational cell therapy for PD. At the same time, first European participants have been randomized in REGENERATE-PD, a Phase II...
Themefolio
Profiler
Peergroup
© BusinessWire
15.09.2025
BAYN
LISTED
XETR
10 Years of Supporting Rural America: Bayer and Luke Bryan Team Up with Feeding America® to Tackle Hunger with “Take Care, Now” Campaign
News Preview
Bayer today announced a milestone in its Take Care, Now campaign with country superstar and five-time Entertainer of the Year, Luke Bryan, and Feeding America®, the nation’s largest hunger-relief organization. The effort builds on last year’s success to address both food insecurity and “hidden hunger” – nutrient gaps that can impact long-term heal...
Themefolio
Profiler
Peergroup
© BusinessWire
27.08.2025
BAYN
LISTED
XETR
Gadoquatrane New Drug Application Accepted for Review by U.S. FDA
News Preview
Bayer today announced that a New Drug Application (NDA) for its investigational contrast agent gadoquatrane has been accepted for review by the U.S. Food and Drug Administration (FDA). The NDA for gadoquatrane has been filed for contrast-enhanced magnetic resonance imaging of the central nervous system (CNS) and other body regions in adults and pe...
Themefolio
Profiler
Peergroup
© BusinessWire
18.08.2025
BAYN
LISTED
XETR
Monsanto Reaches Agreements in Principle to Resolve Additional PCB Cases at the Sky Valley Education Center
News Preview
Monsanto has now reached agreements in principle to resolve all Sky Valley Education Center cases, representing more than 200 plaintiffs overall, with the exception of the prior adverse verdicts that remain on appeal. The Sky Valley Education Center cases involve allegations of injuries due to exposure to polychlorinated biphenyls (PCBs) at the sc...
Themefolio
Profiler
Peergroup
© BusinessWire
15.08.2025
BAYN
LISTED
XETR
Bayer® Aspirin Introduces Aspirina to the U.S. Pain Market
News Preview
Bayer’s Aspirina, the #1 pain relief option in Mexico1, is now available for purchase in the United States, bringing a well-known brand to the Hispanic community. With a deep commitment to Hispanic consumers, Aspirina is poised to provide an accessible and effective solution for pain relief.
As the Hispanic population in the U.S. continues to gr...
Themefolio
Profiler
Peergroup
© EQS Newswire
31.07.2025
BAYN
LISTED
XETR
Bayer hebt währungsbereinigte Umsatz- und Ergebnisprognose für 2025 an und erhöht Rückstellungen für Rechtsstreitigkeiten in den USA
News Preview
Leverkusen, 31. Juli 2025 – Vor der Bekanntgabe der Geschäftsentwicklung des zweiten Quartals 2025 am Mittwoch, 6. August, informiert die Bayer AG über wesentliche Finanzkennzahlen. Für das Gesamtjahr 2025 hebt Bayer die währungsbereinigte (wb.) Umsatz- und Ergebnisprognose an, da sich das Geschäft der Division Pharmaceuticals im ersten Halbjahr be......
Themefolio
Profiler
Peergroup
© EQS Newswire
31.07.2025
BAYN
LISTED
XETR
Bayer upgrades currency-adjusted sales and earnings guidance for 2025 and establishes additional provisions for litigation in the United States
News Preview
Leverkusen, July 31, 2025 – Ahead of the publication of its business results for the second quarter of 2025 on Wednesday, August 6, Bayer AG is providing an update on key financial figures. Due to a better-than-expected business performance at Pharmaceuticals in the first half of the year, Bayer is raising its full-year guidance for currency-adjust......
Themefolio
Profiler
Peergroup
© BusinessWire
20.01.2025
BAYN
LISTED
XETR
Leaps by Bayer Announces One of the Largest Global Surveys of Society’s Attitudes Toward Breakthrough Technologies
News Preview
As leaders gather for the World Economic Forum Annual Meeting 2025 in Davos, Leaps by Bayer, the impact investing arm of Bayer, and Boston Consulting Group (BCG) announced the launch of one of the largest surveys examining global public sentiment towards transformative technology. The field work was conducted by market research company Ipsos. The...
Themefolio
Profiler
Peergroup
© EQS Newswire
19.02.2024
BAYN
LISTED
XETR
Bayer will Dividendenpolitik anpassen, um Schulden abzubauen
News Preview
Leverkusen, 19. Februar 2024 – Die Bayer AG plant, ihre Dividendenpolitik zu ändern und für drei Jahre das gesetzlich geforderte Minimum auszuschütten. Dieser Schritt ist das Ergebnis einer Überprüfung der Prioritäten bei der Kapitalallokation, um die Verschuldung des Unternehmens zu reduzieren. Für das Geschäftsjahr 2023 ergäbe sich daraus eine Di......
Themefolio
Profiler
Peergroup
© EQS Newswire
19.02.2024
BAYN
LISTED
XETR
Bayer plans to amend its dividend policy to reduce debt
News Preview
Leverkusen, February 19, 2024 – Bayer AG plans to amend its dividend policy to pay out the legally required minimum for three years. This follows a review of the company’s capital allocation priorities to reduce debt. This change would result in a dividend of 0.11 euros per share for fiscal year 2023. The Board of Management and the Supervisory Boa......
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
